Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731271 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
A Phase 1 study of Colorectal Adenocarcinoma and Locally Advanced Solid Tumor, sponsored by Suzhou Transcenta Therapeutics Co..
- Active
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
- 3
- Study locations
NCT05731271: Active Phase 1 study of Colorectal Adenocarcinoma and Locally Advanced Solid Tumor, sponsored by Suzhou Transcenta Therapeutics Co..
NCT05731271 is a Phase 1 study of Colorectal Adenocarcinoma and Locally Advanced Solid Tumor that is active but no longer recruiting, run by Suzhou Transcenta Therapeutics Co.. The registered enrollment target is 111 participants, below the 313-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05731271, a Phase 1 study of Colorectal Adenocarcinoma and Locally Advanced Solid Tumor, is active but no longer recruiting, sponsored by Suzhou Transcenta Therapeutics Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question\[s\] it aims to answer are: * What is the recommended dose patients can safely receive? * How long does this drug remain in the body after administration? * What are the side effects of this drug? * Does your cancer respond to TST003? * Participants on this study will get TST003 intravenously (through a needle into your vein), once every 3 weeks. * You may need to come to the study site 2-4 times to have tests to see if you are eligible to be in the study before you begin to receive the study drug. * After you start the study drug, you will need to return to the site several times after each dose so the physician can take vital signs, draw blood samples, and evaluate you for safety and wellbeing. * Participants will continue taking the drug as long as they are receiving clinical benefit. * At the end of your study participation, additional testing is required.
Primary Outcome
Assess the Dose limiting toxicities experienced
Conditions Studied
Interventions
- DRUG TST003
Study Locations (3)
Texas
- Mary Crowley - Dallas
- NEXT Oncology - San Antonio
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05731271 still lists
NCT05731271 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 313-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which TST003 is the first listed.
NCT05731271 reports a single indexed study location in Texas, Oregon.
Frequently Asked Questions
What is clinical trial NCT05731271 about?
NCT05731271 is a clinical study titled "A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors". The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question\[s\] it aims to answer are: * What is the recommended dose patients can safely receive? * How long does this drug remain in the body after administration? * What are the side effects of this ...
What is the current status of trial NCT05731271?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2023-02-08. Estimated completion is 2026-12.
What conditions does trial NCT05731271 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma, Locally Advanced Solid Tumor, Metastatic Tumor.
What interventions are being tested in trial NCT05731271?
The interventions under investigation include: TST003 (DRUG).
Who is sponsoring clinical trial NCT05731271?
This trial is sponsored by Suzhou Transcenta Therapeutics Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05731271 being conducted?
This trial has 3 study locations across Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05731271's enrollment target sits among peer trials
111 10th of 19 higher than 10 of 19 other Colorectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
RECRUITING · Phase 1
-
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
RECRUITING · Phase 1
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI